Belite Bio (BLTE) Research & Development (2022 - 2026)

Belite Bio (BLTE) has reported Research & Development for 5 consecutive years, with $15.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development rose 66.68% year-over-year to $15.7 million; the TTM figure through Mar 2026 stood at $36.0 billion (up 55.26% YoY), while the FY2025 annual figure was $45.4 million, up 51.56% from the prior year.
• Research & Development came in at $15.7 million for Q1 2026 at Belite Bio, down from $14.6 billion in the prior quarter.
• The five-year high for Research & Development was $14.6 billion in Q4 2025, with the low at $4.9 million in Q4 2023.
• Average Research & Development over 5 years is $5.0 billion, with a median of $5.6 billion recorded in 2023.
• Across the five-year window, Research & Development surged 149097.86% in 2024 and tumbled 99.86% in 2025, its largest moves.
• Year by year, Research & Development stood at $5.2 million in 2022, then retreated by 6.97% to $4.9 million in 2023, then soared by 149097.86% to $7.3 billion in 2024, then jumped by 101.6% to $14.6 billion in 2025, then sank by 99.89% to $15.7 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $15.7 million, $14.6 billion, and $10.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.